Dr. Erica Schwartz, President Donald Trump’s nominee to head the U.S. Centers for Disease Control and Prevention (CDC), faced intense scrutiny from lawmakers during her Senate confirmation hearing as questions mounted over whether she could safeguard the agency from political influence.
Several senators challenged Schwartz on how she would respond if asked to support decisions that conflict with established scientific evidence, particularly under the leadership of Health Secretary Robert F. Kennedy Jr., whose handling of vaccine policy has generated widespread debate.
Schwartz assured lawmakers that scientific evidence would remain at the center of her leadership.
“I will never betray the science,” she told the Senate Health Committee, promising to lead the CDC with what she described as “radical transparency” in an effort to restore confidence in the agency.
Lawmakers Probe Her Relationship With RFK Jr.
Despite those assurances, Democratic senators repeatedly questioned whether Schwartz would be willing to push back against directives from Kennedy if they contradicted scientific recommendations.
Throughout the hearing, Schwartz declined to openly criticize several of Kennedy’s controversial public health decisions, prompting concerns that she may not act independently if confirmed.
Senators sought clear answers on how she would respond if ordered to alter vaccine guidance or suspend public health campaigns, but Schwartz generally avoided committing to hypothetical scenarios.
Vaccine Policy Dominates Confirmation Hearing
One of the most pointed exchanges came when Senator Maggie Hassan questioned whether Schwartz would refuse an order to halt promotion of flu vaccinations during a severe influenza outbreak.
Rather than offering a direct commitment, Schwartz said she preferred not to speculate about hypothetical situations.
Hassan pushed back, arguing the concern was grounded in reality and referenced previously disclosed internal CDC communications indicating that similar directives had already been issued under Kennedy’s leadership.
Although Schwartz acknowledged that current scientific evidence shows no connection between childhood vaccinations and autism, she declined to promise immediate action regarding a CDC webpage that critics say suggests otherwise, explaining that she had not yet reviewed the material.
Military Background Shapes Her Public Health Experience
Schwartz, 54, brings decades of military medical experience to the nomination.
She previously oversaw healthcare services for the U.S. Coast Guard, managing dozens of clinics and medical facilities while supervising vaccination programs for service members.
She later served as deputy surgeon general, helping coordinate uniformed health professionals assigned to federal agencies, including the CDC.
If confirmed, she would take charge of an agency responsible for protecting Americans against infectious diseases, environmental threats, and other major public health risks.
CDC Continues to Recover From Leadership Turmoil
Schwartz’s nomination comes during a period of significant instability at the CDC.
Since Trump returned to office, the agency has experienced major staffing reductions through layoffs and resignations, losing more than a quarter of its workforce.
At the same time, several temporary directors have cycled through leadership positions, contributing to declining employee morale and uncertainty about the agency’s direction.
Public health experts say the CDC has struggled to maintain the level of national leadership it once provided during disease outbreaks and other health emergencies.
Some officials argue that state and local health departments are increasingly being forced to make critical decisions independently rather than relying on coordinated federal guidance.
Previous Leadership Changes Raise Fresh Concerns
The hearing also revived discussion about the Trump administration’s earlier attempts to appoint a permanent CDC director.
Its first nominee, former Congressman Dr. David Weldon, never reached a confirmation vote after his hearing was canceled shortly before it was scheduled to begin.
The administration later nominated Susan Monarez, who briefly served as CDC director after Senate confirmation before being removed from the position less than a month later because officials said she was not aligned with the administration’s priorities.
Her dismissal prompted several senior CDC scientists to resign, warning that political considerations were beginning to outweigh scientific independence within the agency.
Nominee Says CDC Should Refocus on Core Mission
During Wednesday’s hearing, Schwartz argued that the CDC should concentrate more heavily on infectious disease control and emergency preparedness.
She suggested the agency had gradually expanded beyond its original responsibilities, saying it had attempted to become “all things to all people.”
At the same time, she agreed to review issues raised by Republican senators, including concerns about potential health effects linked to artificial intelligence data centers and the possibility of establishing a World Trade Center Health Program clinical center in Florida.
Financial Disclosures and Ethics Commitments
Ahead of the confirmation process, Schwartz submitted ethics filings outlining plans to step away from her private-sector roles if confirmed.
She pledged to resign from her position at UnitedHealth Group, where she currently earns approximately $850,000 annually in salary and bonuses, and to divest related financial interests.
She also committed to leaving board positions at Butterfly Network Inc., Aveanna Healthcare, and the Searching for Solutions Institute to avoid potential conflicts of interest.
Emergency Preparedness Nominee Also Questioned
The Senate committee also examined the nomination of Sean Kaufman for Assistant Secretary for Preparedness and Response, the office responsible for coordinating federal responses to health emergencies and disasters.
Lawmakers questioned Kaufman about past social media posts criticizing the CDC, his previous support for individuals who refused COVID-19 vaccines, and his skepticism toward hepatitis B vaccinations for newborns.
He also faced criticism over his support for the administration’s decision to cancel hundreds of millions of dollars in funding for research involving mRNA vaccine technology.
Kaufman Defends Position on mRNA Research
Kaufman told senators he believes mRNA vaccines are both safe and effective and supports the technology’s future development.
However, he argued that additional evaluation of previous research remains appropriate before committing further investment, saying continued study could improve understanding of possible side effects.
Some lawmakers disagreed, warning that slowing research into mRNA vaccines could weaken the country’s ability to respond quickly to future pandemics and emerging infectious diseases.
The confirmation hearings underscored the growing political divide surrounding America’s public health agencies, with lawmakers continuing to debate how scientific decision-making should be protected while rebuilding confidence in institutions that have faced years of leadership upheaval.
